Patients with gender dysphoria are increasingly seeking gender-affirming therapies, which can have adverse hematologic effects. For example, estrogen can increase the risk for arterial and venous thrombosis, whereas testosterone can cause erythrocytosis. This article reviews the hematologic issues associated with gender-affirming hormone therapies and discusses ways to lessen and monitor the risks. Common consult scenarios are also addressed.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
hematologic concerns
4
concerns transgender
4
transgender patients
4
patients patients
4
patients gender
4
gender dysphoria
4
dysphoria increasingly
4
increasingly seeking
4
seeking gender-affirming
4
gender-affirming therapies
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!